Agenus Secures Up to $340 Million in Private Financing to Advance Phase 3 ROBBIN Trial for MSS Colon Cancer
Agenus Inc., a biotechnology company focused on developing innovative immuno-oncology therapies, has announced that it has entered into a securities purchase agreement for a private placement expected to provide approximately $85 million in upfront gross proceeds, with the potential to raise up to an additional $255 million through the full exercise of accompanying purchase warrants. If all warrants are exercised, the financing could generate up to $340 million in gross proceeds before expenses.
The financing was led by Commodore Capital, with participation from a group of prominent life sciences investors including RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. According to Agenus, the funding will primarily support the company’s strategic focus on advancing botensilimab (BOT) in combination with balstilimab (BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including the planned registrational Phase 3 ROBBIN1 clinical trial.
The investment marks an important milestone for Agenus as it concentrates resources on a program that has generated encouraging early clinical results in a patient population with limited treatment innovation over the past two decades. The company believes that prioritizing neoadjuvant immunotherapy for high-risk Stage II and Stage III MSS colon cancer has the potential to significantly improve long-term outcomes while addressing a substantial unmet medical need.
Financing Supports Long-Term Development Strategy
Under the terms of the private placement, Agenus will issue shares of common stock—or pre-funded warrants in certain cases—to participating investors, generating approximately $85 million in upfront funding.
In addition, investors will receive Series A and Series B purchase warrants. Should these warrants be exercised in full, the company would receive approximately $255 million in additional gross proceeds, bringing the total financing to as much as $340 million.
Agenus stated that both the purchase price for the common stock and the exercise prices for the warrants were established at a premium to the company’s market closing price on July 10, 2026, reflecting investor confidence in the company’s strategic direction and development pipeline.
The private placement is expected to close around July 15, 2026, subject to customary closing conditions.
Funding Expected Through Completion of Phase 3 Program
The company indicated that if all warrants are exercised, the financing is expected to provide sufficient capital to complete the planned ROBBIN Phase 3 study while extending the company’s operational runway through the end of 2031.
This long-term financial support is intended to allow Agenus to execute its registrational clinical strategy without requiring significant additional financing during the development program.
By securing funding early, the company aims to maintain focus on clinical execution while reducing uncertainty surrounding future capital requirements.
Focusing on High-Risk MSS Colon Cancer
The primary objective of the financing is to accelerate development of botensilimab plus balstilimab (BOT+BAL) as a neoadjuvant immunotherapy regimen for patients with high-risk Stage II and Stage III microsatellite-stable colon cancer.
Microsatellite-stable disease represents the overwhelming majority of colorectal cancers.
Unlike microsatellite instability-high (MSI-H) tumors, which often respond well to immune checkpoint inhibitors, MSS colorectal cancers have historically shown limited responsiveness to currently available immunotherapies.
This biological resistance has made MSS colon cancer one of the most difficult settings in which to successfully apply checkpoint inhibitor therapy.
According to Agenus, approximately 38,000 patients each year in the United States and more than 200,000 patients globally are diagnosed with high-risk Stage II or Stage III MSS colon cancer.
The company estimates this represents an annual addressable commercial opportunity exceeding $7 billion, while noting that no new curative-intent therapies have been approved for this patient population in more than 20 years.
Why Neoadjuvant Treatment Matters
Neoadjuvant therapy refers to treatment administered before surgical removal of the tumor.
Increasing evidence suggests that exposing an intact tumor to immunotherapy prior to surgery may stimulate a stronger and broader immune response than treating patients after the tumor has already been removed.
This strategy has produced meaningful improvements in several other cancers, including melanoma and certain forms of lung cancer.
Agenus believes its BOT+BAL combination may similarly benefit patients with MSS colon cancer despite the historically poor responsiveness of these tumors to conventional checkpoint inhibitors.
Encouraging Phase 2 Clinical Results
The company’s strategic decision is supported by findings from two independent Phase 2 studies:
- NEST
- UNICORN
Both studies evaluated neoadjuvant BOT+BAL in patients with microsatellite-stable colorectal cancer.
Across these trials, the investigational combination demonstrated encouraging pathological responses.
According to Agenus:
- Approximately 60–70% of patients achieved a pathologic response (PR)
- Approximately 35–40% achieved a major pathologic response (MPR)
- Approximately 30% achieved a pathologic complete response (pCR)
Pathologic complete response indicates that no residual viable cancer cells are detectable in tissue removed during surgery following treatment.
Major pathologic response reflects only minimal remaining viable tumor.
These outcomes have become increasingly important surrogate markers in oncology because they are often associated with improved long-term clinical outcomes.
Early Disease Control Remains Encouraging
The company also reported encouraging follow-up observations from the Phase 2 studies.
With median follow-up ranging from approximately nine to eighteen months, Agenus stated that all treated patients remained disease free at the time of reporting.
Although longer observation will be required to confirm durable benefit, these preliminary findings have strengthened the company’s confidence in advancing the program into registrational development.
Additional updates from the NEST and UNICORN studies are expected later this year.
ctDNA Findings Support Development Strategy
Beyond pathological responses, Agenus also reported encouraging findings involving circulating tumor DNA (ctDNA).
Clearance of ctDNA following treatment is increasingly recognized as an important biomarker associated with reduced recurrence risk in several cancers.
According to the company, observed ctDNA clearance during BOT+BAL treatment further supports the biological activity of the combination regimen and reinforces the rationale for continued development.
These molecular findings complement the pathological response data generated in the Phase 2 studies.
The Planned ROBBIN Phase 3 Trial
The company’s primary clinical focus is now the planned ROBBIN registrational trial.
ROBBIN will be a global, randomized Phase 3 study evaluating BOT+BAL administered before surgery in patients with previously untreated high-risk Stage II and Stage III MSS colon cancer.
Approximately 850 patients are expected to be enrolled.
Participants will be randomized in a 1:1 ratio to receive either:
- BOT+BAL followed by standard-of-care treatment, or
- Standard-of-care treatment alone.
The trial’s primary endpoint will be event-free survival (EFS).
Event-free survival measures the time patients remain free from disease recurrence, progression, or other predefined clinical events.
Alignment with FDA
Agenus stated that it has held discussions with the U.S. Food and Drug Administration regarding the design of the Phase 3 study.
According to the company, agreement has been reached on several key elements of the trial, including:
- Target patient population
- Experimental treatment regimen
- Control arm
- Primary endpoint
- Interim analysis strategy
Regulatory alignment prior to trial initiation helps reduce uncertainty and supports efficient execution of registrational studies.
Scientific Perspective
Dr. Steven O’Day, Chief Medical Officer of Agenus, explained that immunotherapy has already transformed treatment for several immunologically active cancers, including melanoma and lung cancer.
However, microsatellite-stable colon cancer has historically remained resistant to conventional checkpoint inhibitors because it is considered an immunologically “cold” tumor.
According to Dr. O’Day, botensilimab was specifically engineered to overcome these resistance mechanisms.
He noted that the encouraging pathological responses observed in both the NEST and UNICORN studies provide a strong scientific rationale for evaluating the combination in earlier-stage disease where immune activation may have the greatest opportunity to improve long-term outcomes.
Strategic Portfolio Prioritization
To concentrate financial and operational resources on the ROBBIN program, Agenus announced that it plans to discontinue financial support for the ongoing BATTMAN Phase 3 study, which is evaluating BOT+BAL in patients with late-line metastatic MSS colorectal cancer.
The company emphasized that it will continue meeting its obligations to patients already receiving treatment and intends to work closely with the Canadian Cancer Trials Group (CCTG) and participating investigators to ensure a responsible transition.
Agenus also expressed appreciation to the physicians, clinical sites, research teams, and patients who contributed to the BATTMAN program.
Leadership Commentary
Founder, Chairman, and Chief Executive Officer Dr. Garo H. Armen stated that Agenus has spent more than three decades pursuing therapies capable of harnessing the immune system to improve cancer outcomes.
According to Dr. Armen, prioritizing neoadjuvant BOT+BAL reflects both the strength of the emerging clinical evidence and the opportunity to bring potentially meaningful treatment advances to patients at an earlier stage of disease.
He noted that the ROBBIN study is specifically designed to confirm the rapid and deep responses previously observed in the Phase 2 NEST and UNICORN trials.
Upcoming Clinical Milestones
Agenus outlined several anticipated milestones for the ROBBIN development program:
- First patient enrollment: Expected during the first quarter of 2027
- Interim pathological response analysis: Anticipated in the second half of 2027
- Interim event-free survival analysis: Expected in the second half of 2029
- Final event-free survival analysis: Planned for the second half of 2030
These milestones will provide important information regarding both the biological activity and long-term clinical benefit of the investigational combination.
The private placement provides Agenus with significant financial resources to advance one of its highest-priority oncology programs while reinforcing investor confidence in the company’s immunotherapy strategy. With the potential to generate up to $340 million in gross proceeds, the financing is expected to support the completion of the pivotal ROBBIN Phase 3 trial and extend the company’s operational runway through 2031 if all warrants are exercised.
Supported by encouraging Phase 2 pathological response data, early evidence of sustained disease control, and regulatory alignment on trial design, Agenus is positioning botensilimab plus balstilimab as a potential neoadjuvant immunotherapy option for patients with high-risk microsatellite-stable colon cancer—a disease setting where therapeutic innovation has remained limited for decades. If future studies confirm the promising early findings, the program could represent an important advance in expanding the benefits of immunotherapy to a broader population of colorectal cancer patients.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches. Agenus’ headquarters are in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
About Botensilimab (BOT)
Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Approximately 1,300 patients have been treated with BOT and/or BAL in phase 1 and phase 2 clinical trials. BOT alone, or in combination with Agenus’ investigational PD-1 antibody, BAL, has shown clinical responses across nine metastatic, late-line cancers. For more information about BOT trials, visit www.clinicaltrials.gov.
About Balstilimab (BAL)
Balstilimab (BAL) is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
About the ROBBIN Phase 3
ROBBIN is Agenus’ planned randomized global Phase 3 trial evaluating BOT+BAL in high-risk Stage II/III MSS/pMMR colon cancer. The trial is designed to assess whether a short-course neoadjuvant BOT+BAL regimen administered before surgery can generate deep pathologic and molecular responses and improve longer-term clinical outcomes, including event-free survival.
The proposed ROBBIN design includes neoadjuvant BOT+BAL followed by surgery and guideline-directed adjuvant chemotherapy or observation based on pathologic staging, compared with the current standard of care of surgery followed by guideline-directed adjuvant chemotherapy or observation. The primary endpoint is event-free survival. Key secondary and exploratory endpoints are expected to include overall survival, circulating tumor DNA negativity, quality of life, safety, pathologic response, and other measures.